Rheumatoid Arthritis Pipeline and Clinical Trials Assessment: FDA Approvals, Therapies and Key Companies involved by DelveInsight | OncoOne, Oryn Therapeutic, I-Mab Biopharma Co. Ltd., Teijin Pharma, Revolo Biotherapeutics, Eli Lilly and Company

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Rheumatoid Arthritis pipeline constitutes 95+ key companies continuously working towards developing 100+ Rheumatoid Arthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Rheumatoid Arthritis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rheumatoid Arthritis Market.

The Rheumatoid Arthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Rheumatoid Arthritis Pipeline Report: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Rheumatoid Arthritis treatment therapies with a considerable amount of success over the years.
• Rheumatoid Arthritis companies working in the treatment market are Sonoma Biotherapeutics, OncoOne, Oryn Therapeutic, I-Mab Biopharma Co. Ltd., Teijin Pharma, Revolo Biotherapeutics, Eli Lilly and Company, Philogen, SynAct Pharma, RemeGen, SinoMab Bioscience, and others, are developing therapies for the Rheumatoid Arthritis treatment
• Emerging Rheumatoid Arthritis therapies in the different phases of clinical trials are- SBT-77-7101, ON104, ORTD 1, TJ003234, TCK-276, IRL-201805, LY3462817, Dekavil, AP1189, RC18, SM0, and others are expected to have a significant impact on the Rheumatoid Arthritis market in the coming years
• In February 2022, Biogen Inc. and Xbrane Biopharma AB have joined forces through a commercialization and license agreement for the development, manufacturing, and commercialization of Xcimzane™. This preclinical monoclonal antibody is intended as a proposed biosimilar referencing CIMZIA® (certolizumab pegol).
• In June 2022, Biogen Inc. and Bio-Thera Solutions, Ltd. have shared positive results from Phase III trials of BIIB800 (BAT1806), a biosimilar candidate referencing tocilizumab. The double-blind 52-week study, involving 621 patients with moderate to severe rheumatoid arthritis, randomly assigned participants to receive either BIIB800 or the reference tocilizumab intravenously every 4 weeks at a dose of 8 mg/kg for the initial 24 weeks. The data from the Phase III comparative clinical trial indicated that the investigational biosimilar candidate BIIB800 demonstrated equivalent efficacy and a comparable safety and immunogenicity profile to the reference tocilizumab product.
• In February 2022, The FDA in the United States has agreed to review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA (adalimumab-afzb) as an interchangeable biosimilar to Humira (adalimumab).
• In February 2022, Biogen Inc. and Xbrane Biopharma AB have joined in a commercialization and license pact to advance, produce, and market Xcimzane. This preclinical monoclonal antibody serves as a suggested biosimilar referencing CIMZIA (certolizumab pegol), targeting the treatment of rheumatoid arthritis.

Rheumatoid Arthritis Overview
Rheumatoid arthritis (RA) is a chronic autoimmune disorder that primarily affects the joints. It causes inflammation, pain, swelling, and stiffness in the affected joints, and over time, it can lead to joint damage and deformities. Rheumatoid arthritis is one of the most common forms of inflammatory arthritis.

Get a Free Sample PDF Report to know more about Rheumatoid Arthritis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Rheumatoid Arthritis Drugs Under Different Phases of Clinical Development Include:
• SBT-77-7101: Sonoma Biotherapeutics
• ON104: OncoOne
• ORTD 1: Oryn Therapeutic
• TJ003234: I-Mab Biopharma Co. Ltd.
• TCK-276: Teijin Pharma
• IRL-201805: Revolo Biotherapeutics
• LY3462817: Eli Lilly and Company
• Dekavil: Philogen
• AP1189: SynAct Pharma
• RC18: RemeGen
• SM03: SinoMab Bioscience
• TS152: Taisho Pharmaceutical
• SM03: SinoMab
• SHR0302: Jiangsu Hengrui Medicine
• RC18: RemeGen
• Otilimab: GlaxoSmithKline
• ATI-450: Aclaris Therapeutics
• MBS2320: Modern Biosciences
• PF-06651600: Pfizer
• Obefazimod: Abivax
• ABBV-154: AbbVie
• Branebrutinib: Bristol Myers Squibb
• KPL-404: Kiniksa Pharmaceuticals
• ORTD-1: Oryn Therapeutics
• MRx0006: 4D pharma plc.
• LABP-69: Landos Biopharma, Inc
• BZ068: Biozeus

Rheumatoid Arthritis Route of Administration
Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Rheumatoid Arthritis Molecule Type
Rheumatoid Arthritis Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Rheumatoid Arthritis Pipeline Therapeutics Assessment
• Rheumatoid Arthritis Assessment by Product Type
• Rheumatoid Arthritis By Stage and Product Type
• Rheumatoid Arthritis Assessment by Route of Administration
• Rheumatoid Arthritis By Stage and Route of Administration
• Rheumatoid Arthritis Assessment by Molecule Type
• Rheumatoid Arthritis by Stage and Molecule Type
DelveInsight's Rheumatoid Arthritis Report covers around 100+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Rheumatoid Arthritis product details are provided in the report. Download the Rheumatoid Arthritis pipeline report to learn more about the emerging Rheumatoid Arthritis therapies at:

Some of the key companies in the Rheumatoid Arthritis Therapeutics Market include:
Key companies developing therapies for Rheumatoid Arthritis are - Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., and others.

Rheumatoid Arthritis Pipeline Analysis:
The Rheumatoid Arthritis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Rheumatoid Arthritis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rheumatoid Arthritis Treatment.
• Rheumatoid Arthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Rheumatoid Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rheumatoid Arthritis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Rheumatoid Arthritis drugs and therapies-

Rheumatoid Arthritis Pipeline Market Drivers
• Rising prevalence of arthritis and other joint disorders, rising combinational therapy of biologics for the treatment of Rheumatoid Arthritis, rich emerging pipeline, acceptance of biosimilars for treatment of Rheumatoid Arthritis are some of the important factors that are fueling the Rheumatoid Arthritis Market.

Rheumatoid Arthritis Pipeline Market Barriers
• However, high cost of biologics, low adherence to the drugs, lack of daily assessment of RA • Delay in RA diagnosis and other factors are creating obstacles in the Rheumatoid Arthritis Market growth.

Scope of Rheumatoid Arthritis Pipeline Drug Insight
• Coverage: Global
• Key Rheumatoid Arthritis Companies: Sonoma Biotherapeutics, OncoOne, Oryn Therapeutic, I-Mab Biopharma Co. Ltd., Teijin Pharma, Revolo Biotherapeutics, Eli Lilly and Company, Philogen, SynAct Pharma, RemeGen, SinoMab Bioscience, and others
• Key Rheumatoid Arthritis Therapies: SBT-77-7101, ON104, ORTD 1, TJ003234, TCK-276, IRL-201805, LY3462817, Dekavil, AP1189, RC18, SM0, and others
• Rheumatoid Arthritis Therapeutic Assessment: Rheumatoid Arthritis current marketed and Rheumatoid Arthritis emerging therapies
• Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and Rheumatoid Arthritis market barriers

Request for Sample PDF Report for Rheumatoid Arthritis Pipeline Assessment and clinical trials-

Table of Contents
1. Rheumatoid Arthritis Report Introduction
2. Rheumatoid Arthritis Executive Summary
3. Rheumatoid Arthritis Overview
4. Rheumatoid Arthritis- Analytical Perspective In-depth Commercial Assessment
5. Rheumatoid Arthritis Pipeline Therapeutics
6. Rheumatoid Arthritis Late Stage Products (Phase II/III)
7. Rheumatoid Arthritis Mid Stage Products (Phase II)
8. Rheumatoid Arthritis Early Stage Products (Phase I)
9. Rheumatoid Arthritis Preclinical Stage Products
10. Rheumatoid Arthritis Therapeutics Assessment
11. Rheumatoid Arthritis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Rheumatoid Arthritis Key Companies
14. Rheumatoid Arthritis Key Products
15. Rheumatoid Arthritis Unmet Needs
16 . Rheumatoid Arthritis Market Drivers and Barriers
17. Rheumatoid Arthritis Future Perspectives and Conclusion
18. Rheumatoid Arthritis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Rheumatoid Arthritis Market https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Rheumatoid Arthritis Epidemiology https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's 'Rheumatoid Arthritis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.